Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on